Noida Chronicle

According to DelveInsight, the Paroxysmal Nocturnal Hemoglobinuria market in 7MM is expected to witness a major change in the study period 2019-2032

 Breaking News
  • No posts were found

According to DelveInsight, the Paroxysmal Nocturnal Hemoglobinuria market in 7MM is expected to witness a major change in the study period 2019-2032

November 21
10:29 2022

The Paroxysmal Nocturnal Hemoglobinuria Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development.

 

The Paroxysmal Nocturnal Hemoglobinuria market report provides current treatment practices, Paroxysmal Nocturnal Hemoglobinuria emerging drugs, and Paroxysmal Nocturnal Hemoglobinuria market share of the individual therapies, current and forecasted 7MM Paroxysmal Nocturnal Hemoglobinuria market size. The Paroxysmal Nocturnal Hemoglobinuria market research report also covers current Paroxysmal Nocturnal Hemoglobinuria treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Key takeaways from the Paroxysmal Nocturnal Hemoglobinuria Market Research Report

  • The increase in market size is a direct consequence of the increasing incidence of Paroxysmal Nocturnal Hemoglobinuria across the 7MM.
  • According to Harshil et al., most patients affected with PNH fall in the age range of 30 years to 40 years.
  • As per George et al., the risk of developing PNH after treatment for aplastic anemia with immunosuppressive therapy (anti-thymocyte globulin and cyclosporine) is approximately 20-30%.
  • Paroxysmal Nocturnal Hemoglobinuria Market Companies are working such as Alexion Pharmaceuticals, Apellis Pharmaceuticals, Hoffmann-La Roche, Novart, Regeneron Pharmaceuticals, RA Pharmaceuticals Inc., and others.
  • Paroxysmal Nocturnal Hemoglobinuria Pipeline therapies such as Iptacopan (LNP023), Crovalimab, Eculizumab, Danicopan, ACH-0144471, LNP023, C5 Inhibitor, Pozelimab, Cemdisiran, and others.

 

Discover more about therapies set to grab major Paroxysmal Nocturnal Hemoglobinuria market research report @ Paroxysmal Nocturnal Hemoglobinuria Market Size

 

Paroxysmal Nocturnal Hemoglobinuria Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood. This disease is due to mutation of the X-linked gene phosphatidylinositol glycan class A (PIGA), leading to deficiency in the glycosylphosphatidylinositol (GPI) protein, which is responsible for anchoring other protein moieties to the surface of erythrocytes. The disease is characterized by destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function (not making enough of the three blood components). However, the disease presents with a variety of symptoms.

 

Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation in the 7MM

  • Total Paroxysmal Nocturnal Hemoglobinuria Prevalent Cases
  • Paroxysmal Nocturnal Hemoglobinuria Diagnosed Cases
  • Paroxysmal Nocturnal Hemoglobinuria Age-specific Cases

 

Download the report to understand which factors are driving Paroxysmal Nocturnal Hemoglobinuria market trends @ Paroxysmal Nocturnal Hemoglobinuria Market Outlook

 

Paroxysmal Nocturnal Hemoglobinuria Treatment Market

Paroxysmal Nocturnal Hemoglobinuriatreatment is eculizumab, a monoclonal antibody that inhibits C5 in the terminal complement cascade. It revolutionized treatment by near normalizing life expectancy and improving quality of life for patients. The treatment landscape of PNH is now vibrantly evolving with many market launches of recently approved treatments with different MoA. Ravulizumab is a longer acting intravenous C5 inhibitor now licensed by the FDA and EMA, for the treatment of PNH. With different therapeutic targets in the complement cascade and difference modalities of treatment, including subcutaneous, oral and intravenous therapies being developed, increasing independence for patients and reducing healthcare requirements.

 

Paroxysmal Nocturnal Hemoglobinuria Market Insight

The Paroxysmal Nocturnal Hemoglobinuria market is experiencing an influx of several pharmaceutical companies investigating numerous second-generation C5 inhibitors, in different routes of administration to bridge the treatment gap. Key pharmaceutical players such as Apellis Pharmaceuticals, Novartis, Alexion Pharmaceutical, NovelMed Therapeutics, and several others are energetically operating in the domain. The Paroxysmal Nocturnal Hemoglobinuria pipeline therapies involve C3 inhibitors, second-generation C5 Inhibitors, factor D and Factor B inhibitors expected to be launched in the coming decade.

 

Learn more about Paroxysmal Nocturnal Hemoglobinuria therapies in clinical trials @ Paroxysmal Nocturnal Hemoglobinuria Market Share

 

Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies

  • LNP023 (Novartis)
  • NM8074 (NovelMed Therapeutics)
  • APL-2 (Apellis Pharmaceutical)

 

Scope of the Paroxysmal Nocturnal Hemoglobinuria Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Paroxysmal Nocturnal Hemoglobinuria Companies- Alexion Pharmaceuticals, Apellis Pharmaceuticals, Hoffmann-La Roche, Novart, Regeneron Pharmaceuticals, RA Pharmaceuticals Inc., and others.
  • Paroxysmal Nocturnal Hemoglobinuria Pipeline therapies such as Iptacopan (LNP023), Crovalimab, Eculizumab, Danicopan, ACH-0144471, LNP023, C5 Inhibitor, Pozelimab, Cemdisiran, and others.
  • Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment: Paroxysmal Nocturnal Hemoglobinuria current marketed and emerging therapies
  • Paroxysmal Nocturnal Hemoglobinuria Market Dynamics:  Paroxysmal Nocturnal Hemoglobinuria market drivers and barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Paroxysmal Nocturnal Hemoglobinuria Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Paroxysmal Nocturnal Hemoglobinuria Executive Summary

3. Paroxysmal Nocturnal Hemoglobinuria Competitive Intelligence Analysis

4. Paroxysmal Nocturnal Hemoglobinuria: Market Overview at a Glance

5. Paroxysmal Nocturnal Hemoglobinuria: Disease Background and Overview

6. Patient Journey

7. Paroxysmal Nocturnal Hemoglobinuria Epidemiology and Patient Population

8. Paroxysmal Nocturnal Hemoglobinuria Treatment Algorithm, Current Treatment, and Medical Practices

9. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs

10. Key Endpoints of Paroxysmal Nocturnal Hemoglobinuria Treatment

11. Paroxysmal Nocturnal Hemoglobinuria Marketed Products

12. Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies

13. Paroxysmal Nocturnal Hemoglobinuria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Paroxysmal Nocturnal Hemoglobinuria Market Outlook

16. Access and Reimbursement Overview of Paroxysmal Nocturnal Hemoglobinuria

17. KOL Views

18. Paroxysmal Nocturnal Hemoglobinuria Market Drivers

19. Paroxysmal Nocturnal Hemoglobinuria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Do you have any queries? Connect with our Business Consultant- Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles